Literature DB >> 29192287

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Paul J Carter1, Greg A Lazar1.   

Abstract

Antibodies are the most rapidly growing drug class and have a major impact on human health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of the best understood and most tractable cell surface and secreted targets with known roles in human diseases have been extensively exploited for antibody drug development. In this Review, we focus on emerging and novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody-drug conjugates, bispecific antibodies and antibody engineering to facilitate more effective delivery. These strategies could enable the pursuit of difficult to hit, less well-understood or previously undruggable targets - the 'high-hanging fruit'.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29192287     DOI: 10.1038/nrd.2017.227

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  295 in total

Review 1.  Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.

Authors:  N Beyersdorf; T Hanke; T Kerkau; T Hünig
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 2.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

Review 3.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

4.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors:  Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

5.  Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview.

Authors:  Louis P Garrison
Journal:  Value Health       Date:  2016-06-28       Impact factor: 5.725

6.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

7.  Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.

Authors:  Rinpei Niwa; Emi Shoji-Hosaka; Mikiko Sakurada; Toyohide Shinkawa; Kazuhisa Uchida; Kazuyasu Nakamura; Kouji Matsushima; Ryuzo Ueda; Nobuo Hanai; Kenya Shitara
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

8.  Marketing approval of mogamulizumab: a triumph for glyco-engineering.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

9.  Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Authors:  Edwin Bremer
Journal:  ISRN Oncol       Date:  2013-06-11

Review 10.  Assessing the Immunogenicity of Biopharmaceuticals.

Authors:  Carlos Pineda; Gilberto Castañeda Hernández; Ira A Jacobs; Daniel F Alvarez; Claudio Carini
Journal:  BioDrugs       Date:  2016-06       Impact factor: 5.807

View more
  184 in total

1.  A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice.

Authors:  Yuanyuan Kuang; Veronica Zorzi; Damiano Buratto; Gaia Ziraldo; Flavia Mazzarda; Chiara Peres; Chiara Nardin; Anna Maria Salvatore; Francesco Chiani; Ferdinando Scavizzi; Marcello Raspa; Min Qiang; Youjun Chu; Xiaojie Shi; Yu Li; Lili Liu; Yaru Shi; Francesco Zonta; Guang Yang; Richard A Lerner; Fabio Mammano
Journal:  EBioMedicine       Date:  2020-06-15       Impact factor: 8.143

2.  Cytosolic delivery of inhibitory antibodies with cationic lipids.

Authors:  Hejia Henry Wang; Andrew Tsourkas
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 3.  Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.

Authors:  Tulsi Ram Damase; Peter B Allen
Journal:  Bioconjug Chem       Date:  2019-01-03       Impact factor: 4.774

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

5.  A Case Study to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate Using Middle-Down Mass Spectrometry.

Authors:  Oscar Hernandez-Alba; Stéphane Houel; Steve Hessmann; Stéphane Erb; David Rabuka; Romain Huguet; Jonathan Josephs; Alain Beck; Penelope M Drake; Sarah Cianférani
Journal:  J Am Soc Mass Spectrom       Date:  2019-08-19       Impact factor: 3.109

6.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

7.  Proteomics for cancer drug design.

Authors:  Amanda Haymond; Justin B Davis; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2019-08-04       Impact factor: 3.940

8.  Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding.

Authors:  Yasunori Watanabe; Snezana Vasiljevic; Joel D Allen; Gemma E Seabright; Helen M E Duyvesteyn; Katie J Doores; Max Crispin; Weston B Struwe
Journal:  Anal Chem       Date:  2018-05-25       Impact factor: 6.986

9.  Laboratory mice born to wild mice have natural microbiota and model human immune responses.

Authors:  Jasmin Herz; Brian G Vassallo; Stephan P Rosshart; Ashli Hunter; Morgan K Wall; Jonathan H Badger; John A McCulloch; Dimitrios G Anastasakis; Aishe A Sarshad; Irina Leonardi; Nicholas Collins; Joshua A Blatter; Seong-Ji Han; Samira Tamoutounour; Svetlana Potapova; Mark B Foster St Claire; Wuxing Yuan; Shurjo K Sen; Matthew S Dreier; Benedikt Hild; Markus Hafner; David Wang; Iliyan D Iliev; Yasmine Belkaid; Giorgio Trinchieri; Barbara Rehermann
Journal:  Science       Date:  2019-08-01       Impact factor: 47.728

10.  Systematic Activity Maturation of a Single-Domain Antibody with Non-canonical Amino Acids through Chemical Mutagenesis.

Authors:  Philip R Lindstedt; Francesco A Aprile; Pietro Sormanni; Robertinah Rakoto; Christopher M Dobson; Gonçalo J L Bernardes; Michele Vendruscolo
Journal:  Cell Chem Biol       Date:  2020-11-19       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.